Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Ovarian Cancer.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women's Hospital, is the corresponding author of a ...

A paper published in the Journal of Clinical Oncology, titled "Comparative Analysis of Intracranial Response Assessment ...

During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...

Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women’s Hospital, is the corresponding author of a paper published in the Journal of Clinical Oncology, “Comparative Analysis ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Researchers concluded that dabrafenib and trametinib appeared active in the second-line adjuvant setting, “although more follow up is required to confirm.” ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for ...

Becomes the first subcutaneously administered PD-1 inhibitor.